Ok , based on your criteria , I too am frustrated . I bought the stock for HIV and cancer about 6 weeks before covid came along. It’s apparent before we hired new additions in Q4 of last year , our management was not the best in managing Amarex and understanding the definitions of the trials for covid which were created. Somehow we did get thru the HIV trials but we didn’t have expertise in dealing with BLAs so that blew up . So that expertise needs to rise to the top quickly. First , get that BLA filed . There is no longer a clear path to revenue. But HIV is the closest because endpoints were met.I was and am still concerned we spread ourselves too thin , having our fingers in every conceivable pre clinical work and trial work for every application for a Leronlimab. This company has about 20 employees and I believe they over shot the runway in what they bit off here.
I am not going to keep pounding on NP. My opinion is known about him and if he stays in his role, he needs to get at least one of these EUA//full approvals over the finish line in 2021.
So I am a hold . I will buy more if at least one deliverable crosses the finish line .if not , I will exit my position ,regardless of price by the end of the year.